Short courses

New diagnosis of psoriatic arthritis in a patient with plaque psoriasis

Insight

Supplier’s declaration

This activity is offered jointly by National Jewish Health and Catamount Medical Education.


Statement of support

This activity is supported by an independent educational grant from UCB Inc.


Release date: September 16, 2022
Expiration date: September 16, 2023

The estimated time to complete the activity is 15 minutes.

Target audience

Rheumatologists, dermatologists, primary care physicians, nurse practitioners, and PAs involved in caring for patients with psoriatic arthritis (PsA).


Learning objectives

At the end of this activity, participants should be better able to:

  • Discuss considerations for setting treatment goals with individual patients with PsA
  • Use best practices to monitor treatment response and adjust therapy as needed

Faculty

Anthony P. Fernandez, MD, Ph.D.
Director of Medical Dermatology
Cleveland Clinic

Mr. Elaine Husni MD MPH
Vice President, Department of Rheumatic and Immunological Diseases
Director, Arthritis and Musculoskeletal Center
Scholtz Endowed Chair


Peer reviewers

Harold Nelson, MD
Chairman, CME Committee
National Jewish Health

Elizabeth (Lisa) Swanson, MD
Dermatologist and Pediatric Dermatologist
ADA West Dermatology
St. Luke’s Children’s Hospital


Planning Committee

Susan Denner, MD, MS
medical writer
Catamount Medical Education

Jennifer Green
Head of Learning
Catamount Medical Education

Alexa Lask
Project Manager
Catamount Medical Education

Elyce Bowron, M.Ed.
Medical Education Project Specialist
National Jewish Health

Meghan Brenner, MA
Associate Director, Accreditation and Programs
National Jewish Health


Accreditation

This activity was planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint delivery of National Jewish Health and Catamount Medical Education. National Jewish Health is accredited by ACCME to provide continuing medical education for physicians.


Credit designation

Doctors

National Jewish Health designates this material as durable for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

All other healthcare professionals who complete this course will receive a certificate of attendance.


How to participate in this activity and get a CME credit

There is no charge to participate and receive credit for this activity. During the time the activity is available for credit, participants must:

  • Read information from the CME
  • Complete the pretest
  • Listen to the podcast
  • Complete the post-test and evaluation form.

A 100% correct score must be achieved on the post-test to pass the activity. If you do not receive a passing score, you will receive a message informing you that you did not pass the post-test. You can retake the post-test until you pass. Upon completion of the post-test and assessment form, your certificate will be made available immediately.


Disclosures

Financial Relationship Disclosure Policy

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, reviewers, and others in a position to control the content of this activity disclose to learners the presence or Absence of any financial relationship with an ineligible business defined by the ACCME during the 24 months preceding the activity. ACCME defines a “non-qualifying business” as a business whose principal activity is the production, marketing, sale, resale or distribution of healthcare products used by or on patients.

Our goal is to ensure that there is no compromise in the ethical relationship that exists between those who are able to control the content of the activity and those who participate in the activity and their professional duties. respective. All accredited educational activities offered by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation.

All relevant financial relationships between persons in a position to control the content of this activity have been identified and mitigated in accordance with Accredited Continuing Education’s standards of integrity and independence.

Faculty Disclosures

Anthony P. Fernandez, MD, Ph.D.
Dr. Fernandez has served on the advisory board of Bristol Myers Squibb, Boehringer Ingelheim and UCB Inc. He has been a consultant for Biogen and Mallinckrodt and a lecturer for Novartis Pharmaceuticals. He also served as grant support for a medical dermatology fellowship for Pfizer.

Mr. Elaine Husni MD MPH
Dr. Husni has served on the advisory board of Eli Lilly, Novartis Pharmaceuticals, Pfizer and UCB Inc.

Publish staff disclosures

Harold Nelson, MD
Dr. Nelson did not report any relevant financial relationships.

Lisa Swanson, MD
Dr. Swanson has served on the advisory board of Janssen, Lilly, Ortho Dermatologics and Sanofi-Regeneron. She has been a speaker for AbbVie, Lilly, Janssen, Novartis Pharmaceuticals, Pfizer and Ortho-Dermatologics.

Susan Denner, MD, MS
Dr. Denner did not report any relevant financial relationships.

Jennifer Green
Ms. Green did not report any relevant financial relationships.

Alexa Lask
Ms. Lasek did not report any relevant financial relationships.

Elyce Bowron, M.Ed.
Ms. Bowron did not report any relevant financial relationships.

Meghan Brenner, MA
Ms. Brenner did not report any relevant financial relationships.


Unlabeled Use Disclosure

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to publicly disclose any references to unlabeled or experimental use.

No endorsement of unapproved products or uses is made or implied by coverage of such products or uses.

Please refer to the official prescribing information for each product for a discussion of approved indicators, contraindications and warnings.


Disclaimer

National Jewish Health (“NJH”) and its officers, board of directors, faculty, employees, representatives, and other agents (collectively, the “NJH Parties”) shall not be liable for or warrant any content , in any NJH publication or other product (in any medium), or use of or reliance on any such content, and expressly disclaims any liability for such content. All responsibility for the content and use of the product rests solely with the authors or advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer applies to the accuracy, completeness, effectiveness, quality, appearance, ideas or products, as the case may be, of or arising from any statements, references, articles, positions, claimed diagnoses, claimed possible treatments, services, or advertisements, express or implied, contained in any live meeting, publication, online course, or other NJH product.

Further, the Content should not be considered medical advice and is not intended to replace consultation with a qualified healthcare professional. In no event, including negligence, shall either NJH party be liable for DIRECT, INDIRECT, INCIDENTAL, SPECIAL, or CONSEQUENTIAL DAMAGES, or LOST PROFITS resulting from any of the foregoing, regardless of theory legal and whether the applicant has been informed or not. the possibility of such damages.